Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aspire Biopharma Holdings ( (ASBP) ) has shared an announcement.
On April 10, 2026, Aspire Biopharma Holdings stockholders approved a broad set of capital structure changes at a special meeting, including a reverse stock split at a ratio to be set by the board, an increase in authorized common shares from 490 million to 700 million, and authority to adjourn the meeting if additional proxies were needed. Shareholders also cleared Nasdaq-related approvals for issuing more than 19.99% of outstanding common stock through conversion of Series A convertible preferred shares and under an equity line of credit with Arena Business Solutions Global SPC II, moves that expand the company’s flexibility to raise equity financing and support continued Nasdaq listing compliance, but also increase the potential for future dilution of existing holders.
More about Aspire Biopharma Holdings
Aspire Biopharma Holdings, Inc. operates in the biopharmaceutical sector and is listed on the Nasdaq Stock Market. The company issues common and preferred stock to finance its operations and relies on equity facilities and charter amendments to manage its capital structure and maintain exchange listing compliance.
Average Trading Volume: 832,792
Technical Sentiment Signal: Sell
Current Market Cap: $2.74M
Find detailed analytics on ASBP stock on TipRanks’ Stock Analysis page.